HRP970270B1 - Antifungal compositions with improved bioavailability - Google Patents

Antifungal compositions with improved bioavailability

Info

Publication number
HRP970270B1
HRP970270B1 HR970270A HRP970270A HRP970270B1 HR P970270 B1 HRP970270 B1 HR P970270B1 HR 970270 A HR970270 A HR 970270A HR P970270 A HRP970270 A HR P970270A HR P970270 B1 HRP970270 B1 HR P970270B1
Authority
HR
Croatia
Prior art keywords
improved bioavailability
antifungal compositions
antifungal
compositions
bioavailability
Prior art date
Application number
HR970270A
Other languages
English (en)
Inventor
Elvire Colette Baert Lieven
Verreck Geert
Thone Dany
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970270(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP970270A2 publication Critical patent/HRP970270A2/xx
Publication of HRP970270B1 publication Critical patent/HRP970270B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR970270A 1996-05-20 1997-05-20 Antifungal compositions with improved bioavailability HRP970270B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07

Publications (2)

Publication Number Publication Date
HRP970270A2 HRP970270A2 (en) 1998-04-30
HRP970270B1 true HRP970270B1 (en) 2005-02-28

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970270A HRP970270B1 (en) 1996-05-20 1997-05-20 Antifungal compositions with improved bioavailability

Country Status (33)

Country Link
US (4) US6509038B2 (cs)
EP (1) EP0904060B1 (cs)
JP (1) JP3391801B2 (cs)
KR (1) KR19990044257A (cs)
CN (1) CN1165291C (cs)
AR (1) AR007195A1 (cs)
AT (1) ATE255883T1 (cs)
AU (1) AU722101B2 (cs)
BG (1) BG64368B1 (cs)
BR (1) BR9706897B1 (cs)
CA (1) CA2240161C (cs)
CY (1) CY2434B1 (cs)
CZ (1) CZ293841B6 (cs)
DE (1) DE69726729T2 (cs)
DK (1) DK0904060T3 (cs)
EA (1) EA001219B1 (cs)
EE (1) EE03902B1 (cs)
ES (1) ES2212810T3 (cs)
HR (1) HRP970270B1 (cs)
HU (1) HU227745B1 (cs)
ID (1) ID16926A (cs)
IL (1) IL124935A (cs)
MX (1) MX9805418A (cs)
MY (1) MY123827A (cs)
NO (1) NO320495B1 (cs)
NZ (1) NZ330739A (cs)
PL (1) PL188566B1 (cs)
PT (1) PT904060E (cs)
SI (1) SI0904060T1 (cs)
SK (1) SK284145B6 (cs)
TR (1) TR199801225T2 (cs)
TW (1) TW460282B (cs)
WO (1) WO1997044014A1 (cs)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
CN1153570C (zh) * 1997-12-31 2004-06-16 中外制药株式会社 制备依曲康唑口服制剂的方法及组合物
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
TR200001903T2 (tr) 1998-01-07 2000-11-21 Meiji Seika Kaisha, Ltd. Kristalografik açıdan kararlı, şekilsiz sefalosporin bileşimleri ve bunların üretilmesine ilişkin işlem.
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
CN1156461C (zh) * 1999-03-24 2004-07-07 R·P·希拉技术股份有限公司 改良的水溶性药物制剂
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
JP5159012B2 (ja) 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
PL358290A1 (en) * 2000-06-22 2004-08-09 Novartis Ag Pharmaceutical compositions
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
PT1370543E (pt) 2001-02-14 2007-02-28 Tibotec Pharm Ltd Inibidores de protease de vih 2-(amino-substituída)-benzotiazol-sulfonamida de largo espectro
KR100872029B1 (ko) 2001-04-09 2008-12-05 티보텍 파마슈티칼즈 리미티드 광범위 2-(치환된-아미노)-벤즈옥사졸 설폰아미드 ｈｉｖ프로테아제 저해제
EE05307B1 (et) 2001-05-11 2010-06-15 Tibotec Pharmaceuticals Ltd. Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
AU2002317063A (en) * 2001-06-12 2002-12-23 Smartrix Technologies Inc Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
WO2003011254A1 (en) * 2001-07-31 2003-02-13 Capricorn Pharma Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
BR0215260A (pt) 2001-12-21 2004-12-07 Tibotec Pharm Ltd Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
RU2293721C2 (ru) 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
JP4674084B2 (ja) 2002-05-17 2011-04-20 テイボテク・フアーマシユーチカルズ・リミテツド 広域スペクトルの置換ベンズイソキサゾールスルホンアミドｈｉｖプロテアーゼ阻害剤
WO2004004683A1 (en) * 2002-07-04 2004-01-15 Janssen Pharmaceutica N.V. Solid dispersions comprising two different polymer matrixes
WO2004016619A1 (en) 2002-08-14 2004-02-26 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
DE60312636T3 (de) * 2003-01-14 2014-12-24 Acino Pharma Ag Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer
EP1594468A2 (en) * 2003-02-03 2005-11-16 Novartis AG Process for preparing a solid dispersion pharmaceutical product
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
WO2005011702A1 (en) * 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005021486A1 (ja) * 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
US8268885B2 (en) 2003-09-11 2012-09-18 Janssen R&D Ireland Entry inhibitors of the HIV virus
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
JP5073480B2 (ja) 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
CA2564027A1 (en) 2004-05-17 2005-11-24 Tibotec Pharmaceuticals Ltd. 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
CN1953982B (zh) 2004-05-17 2011-07-06 泰博特克药品有限公司 4-取代-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
US7622581B2 (en) 2004-05-17 2009-11-24 Tibotec Pharmaceuticals Ltd. 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
US9504658B2 (en) 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN101443006B (zh) 2004-12-31 2012-10-10 雷迪美国治疗股份有限公司 作为cetp抑制剂的新颖的苄胺衍生物
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP1912625B1 (en) * 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Itraconazole compositions with improved bioavailability
ES2576633T3 (es) * 2005-08-08 2016-07-08 Abbvie Deutschland Gmbh & Co Kg Formas de dosificación con una biodisponibilidad mejorada
ES2403006T3 (es) * 2005-08-22 2013-05-13 The Johns Hopkins University Antagonistas de la vía Hedgehog para tratar enfermedades
EP1991241A4 (en) * 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
MX2008012790A (es) 2006-04-03 2008-10-15 Tibotec Pharm Ltd 3,4-dihidro-imidazo[4,5-b]piridin-5-onas inhibidoras de virus de inmunodeficiencia humana.
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CN101835492B (zh) * 2007-08-21 2012-11-21 德克萨斯州立大学董事会 用于制药应用的热动力学混合
US8821924B2 (en) 2007-09-14 2014-09-02 Wockhardt Ltd. Rhein or diacerein compositions
AU2008303277B2 (en) 2007-09-27 2013-04-04 Wockhardt Limited Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
AU2008329677B2 (en) 2007-11-28 2015-02-19 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome P450 2D6
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011509283A (ja) * 2008-01-11 2011-03-24 シプラ・リミテッド 固体医薬剤形
WO2009105776A1 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20091778A1 (es) * 2008-04-15 2009-11-13 Schering Corp Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
EA200900145A1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20130303628A1 (en) * 2010-10-14 2013-11-14 Abbott Laboratories Curcuminoid solid dispersion formulation
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
EP2744481A4 (en) * 2011-08-16 2015-07-01 Merck Sharp & Dohme USE OF COMBINATIONS OF AN INORGANIC MATRIX AND AN ORGANIC POLYMER FOR THE MANUFACTURE OF STABLE AMOUNT DISPERSIONS
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
WO2013192566A1 (en) 2012-06-21 2013-12-27 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
PT2874607T (pt) * 2012-07-17 2017-08-14 Dow Global Technologies Llc Resumo
MX2015006223A (es) 2012-11-19 2015-09-25 Reddys Lab Ltd Dr Composiciones farmaceuticas de inhibidores cetp.
JP6192244B2 (ja) 2013-01-22 2017-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改良されたバイオアベイラビリティを有する薬学的組成物
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
KR102303883B1 (ko) * 2014-01-16 2021-09-24 뉴트리션 ＆ 바이오사이언시즈 유에스에이 1, 엘엘씨 3d 인쇄용 지지재료
EP3307839B1 (en) * 2015-06-09 2019-02-27 Dow Global Technologies LLC Support materials for 3d printing
EP3454847A4 (en) * 2016-05-09 2019-12-18 Dispersol Technologies, LLC IMPROVED DRUG FORMULATIONS
WO2019043427A1 (en) 2017-09-01 2019-03-07 Jordan Sweden Medical And Sterilization Company FAST SELF-DISPERSION DOSAGE FORMS OF DEFERASIROX
EP3581697B1 (en) 2018-06-11 2023-02-22 The Procter & Gamble Company Photoactivating device for washing machine
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
MX2022002280A (es) * 2019-08-28 2022-04-25 Lubrizol Advanced Mat Inc Dispersiones solidas amorfas de farmaco-polimero usando polimeros de poli(acido acrilico) lineales.
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
EP4392024A1 (en) 2021-08-25 2024-07-03 Basf Se Direct tableting auxiliary composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
ATE5852T1 (de) * 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PL172358B1 (en) * 1992-03-18 1997-09-30 Janssen Pharmaceutica Nv Stereoisomeric form of itraconazole or saperconazole and method of obtaining same
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) * 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) * 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
AU722101B2 (en) 2000-07-20
BG102532A (en) 1999-02-26
US8591948B2 (en) 2013-11-26
EP0904060B1 (en) 2003-12-10
CA2240161A1 (en) 1997-11-27
HK1018002A1 (en) 1999-12-10
EP0904060A1 (en) 1999-03-31
JPH11509238A (ja) 1999-08-17
EA199800571A1 (ru) 1998-12-24
CZ188598A3 (cs) 1998-11-11
HRP970270A2 (en) 1998-04-30
NO320495B1 (no) 2005-12-12
CN1165291C (zh) 2004-09-08
NZ330739A (en) 1999-06-29
DE69726729T2 (de) 2004-12-02
CZ293841B6 (cs) 2004-08-18
ATE255883T1 (de) 2003-12-15
WO1997044014A1 (en) 1997-11-27
HUP9901620A3 (en) 2000-03-28
US20140134244A1 (en) 2014-05-15
HUP9901620A2 (hu) 1999-10-28
DK0904060T3 (da) 2004-04-13
ES2212810T3 (es) 2004-08-01
US20010007678A1 (en) 2001-07-12
CY2434B1 (en) 2004-11-12
US6509038B2 (en) 2003-01-21
SK84898A3 (en) 1999-03-12
NO982599D0 (no) 1998-06-05
MY123827A (en) 2006-06-30
SK284145B6 (sk) 2004-10-05
BG64368B1 (bg) 2004-12-30
US20060263436A1 (en) 2006-11-23
EE9800304A (et) 1999-02-15
ID16926A (id) 1997-11-20
EE03902B1 (et) 2002-12-16
KR19990044257A (ko) 1999-06-25
US20030082239A1 (en) 2003-05-01
DE69726729D1 (de) 2004-01-22
CN1209740A (zh) 1999-03-03
BR9706897B1 (pt) 2010-09-21
US9642806B2 (en) 2017-05-09
NO982599L (no) 1998-11-19
AR007195A1 (es) 1999-10-13
IL124935A (en) 2001-06-14
HU227745B1 (en) 2012-02-28
US7081255B2 (en) 2006-07-25
TW460282B (en) 2001-10-21
TR199801225T2 (xx) 1998-11-23
JP3391801B2 (ja) 2003-03-31
AU2956297A (en) 1997-12-09
BR9706897A (pt) 1999-08-31
CA2240161C (en) 2005-05-24
IL124935A0 (en) 1999-01-26
EA001219B1 (ru) 2000-12-25
PL330931A1 (en) 1999-06-07
MX9805418A (es) 1998-10-31
SI0904060T1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
IL124935A0 (en) Antifungal compositions with improved bioavailability
ZA973344B (en) Antifungal compositions.
HUP9903388A3 (en) Fungicidal composition
IL126979A (en) Antifungal composition with enhanced bioavailability
IL123715A0 (en) Antifungal compositions
GB9714010D0 (en) Composition
HU9700533D0 (en) Microbicidal composition
GB9726777D0 (en) Composition
AU1598399A (en) Injectable antifungal formulations
GB9714461D0 (en) Antifungal agent
GB9818258D0 (en) Antifungal compositions
PL318520A1 (en) Herbicidal composition
GB2331123B (en) Stays
GB2329418B (en) Stays
ZA974338B (en) Anitfungal compositions with improved bioavailability
AU9464398A (en) Novel antifungal compounds
ZA987526B (en) Fungicidal compositions
GB9720096D0 (en) Stays
GB9611006D0 (en) Antifungal compositions
GB9619534D0 (en) Fungicidal composition
GB9603722D0 (en) Antifungal
IL127855A0 (en) Herbicidal composition
GB2330622B (en) Stays
GB9604147D0 (en) Antifungal agents
GB9606552D0 (en) Antifungal proteins

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160412

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20170520